JB 111
Alternative Names: JB-111Latest Information Update: 10 Mar 2024
At a glance
- Originator Jaya Biosciences
- Class Antidementias; Gene therapies
- Mechanism of Action Gene transference; Palmitoyl-protein thioesterase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 12 Feb 2024 Preclinical trials in Alzheimer's disease in USA (Intraventricular) prior to February 2024 (Jaya Biosciences pipeline, February 2024)
- 12 Feb 2024 Preclinical trials in Neurodegenerative disorders in USA (Intraventricular) prior to February 2024 (Jaya Biosciences pipeline, February 2024)
- 12 Feb 2024 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by Jaya Biosciences